Sign in to continue:

Sunday, February 22nd, 2026

Winfull Group Holdings Limited Announces Expected Significant Decrease in Loss for Six Months Ended December 2025

Winfull Group Holdings Limited Announces Expected Significant Decrease in Loss for H2 2025

Winfull Group Holdings Limited (Stock Code: 183), a company incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange, has issued an important announcement regarding its financial results for the six months ended 31 December 2025. This disclosure is in compliance with Rule 13.09(2)(a) of the Hong Kong Listing Rules and the Inside Information Provisions of the SFO.

Key Points from the Announcement

  • Significant Decrease in Loss: The Group expects its loss attributable to owners for the period ending 31 December 2025 to decrease significantly—by approximately 30% to 40% compared to the prior year’s comparable period.
  • Previous Loss: For the six months ended 31 December 2024, the loss attributable to owners was approximately HK\$53 million.
  • Principal Reason: The anticipated improvement is mainly due to a decrease in the fair value loss of investment properties during the reporting period.
  • Management Assessment: The information is based on a preliminary review of unaudited consolidated management accounts; the results are not audited or reviewed by the Company’s auditor.
  • Final Results Pending: The Company is still finalising its interim results for the period. The full interim results will be released in due course.

Shareholder and Investor Considerations

  • Price Sensitivity: The expected reduction in loss for H2 2025 is material and potentially price sensitive. A decrease in loss of this magnitude could positively affect investor sentiment and share value, particularly as the loss is anticipated to be substantially less than the HK\$53 million recorded in H2 2024.
  • Fair Value Adjustment: The primary reason for the improvement is the reduced fair value loss on investment properties, highlighting the importance of property valuations on the Group’s financial performance.
  • Caution Advised: As the figures are based on unaudited management accounts and subject to finalisation, shareholders and potential investors should exercise caution in dealing in the shares until the interim results are officially released.

Corporate Governance

  • The Company is led by Executive Directors Mr. Pong Wilson Wai San and Mr. Lee Wing Yin, along with three Independent Non-Executive Directors: Mr. Koo Fook Sun, Louis; Ms. Yeung Wing Yan, Wendy; and Mr. Liu Tsee Ming.
  • This announcement was authorised by the Board and signed by Executive Director, Pong Wilson Wai San, on 20 February 2026.

Potential Impact on Share Price

The magnitude of the expected loss reduction (30%–40%) is significant and may lead to a positive re-rating of the shares, especially if the market had anticipated continued losses at the previous level. Investors should monitor the forthcoming interim results for further confirmation and details regarding the Group’s financial turnaround.


Disclaimer

This article is for informational purposes only and does not constitute investment advice. The figures discussed are preliminary and unaudited. Investors should exercise caution and consult with professional advisers before making any investment decisions. The final audited results may differ from the estimates provided in this announcement.

View WINFULL GP Historical chart here



Raffles Interior Faces Audit Uncertainty Amid Integrity Issues of Executive Director Zheng Nenghuan (2025-2026)

Raffles Interior Limited – Detailed Inside Information Report Raffles Interior Limited Issues Critical Update on 2025 Annual Audit Progress Amid Integrity Concerns Surrounding Executive Director Summary Raffles Interior Limited (“the Company”, Stock Code: 1376)...

Hansoh Pharmaceutical’s Aumolertinib Mesylate Tablets Approved in EU as Monotherapy for Advanced EGFR-Mutated NSCLC 1

Hansoh Pharmaceutical Group – EU Approval for Aumolertinib Mesylate Tablets Hansoh Pharmaceutical Group Receives Landmark EU Approval for Aumolertinib Mesylate Tablets as Monotherapy in Advanced NSCLC Key Highlights for Investors European Union (EU) Approval:...

Huaibei GreenGold Industry Discloses Procurement Refund and Listing Rules Compliance Update with Huaibei Construction Investment Group

Huaibei GreenGold Industry Investment Co., Ltd. – Key Disclosure Under Listing Rules Huaibei GreenGold Industry Investment Co., Ltd. Announces Material Disclosure Under Listing Rules Key Points of the Announcement Significant Trade Payment and Delay...

   Ad